Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G7051
Compare
Compare
Traded in other countries / regions
AGEN.USAAJ8.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2000-02-04Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.57 | |||||
| Equity-to-Asset | -1.23 | |||||
| Debt-to-Equity | -0.27 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -14.19 | |||||
| Beneish M-Score | -0.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.1 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 7.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 25.92 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.01 | |||||
| 9-Day RSI | 27.23 | |||||
| 14-Day RSI | 35.39 | |||||
| 3-1 Month Momentum % | 11.11 | |||||
| 6-1 Month Momentum % | -26.21 | |||||
| 12-1 Month Momentum % | -71.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.19 | |||||
| Quick Ratio | 0.19 | |||||
| Cash Ratio | 0.17 | |||||
| Days Sales Outstanding | 12.86 | |||||
| Days Payable | 96.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.2 | |||||
| Shareholder Yield % | -47.11 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -17.88 | |||||
| Operating Margin % | -62.83 | |||||
| Net Margin % | -141.9 | |||||
| FCF Margin % | -106.46 | |||||
| ROA % | -79.22 | |||||
| ROIC % | -27.72 | |||||
| 3-Year ROIIC % | -26.67 | |||||
| ROC (Joel Greenblatt) % | -57.93 | |||||
| ROCE % | -250.78 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.08 | |||||
| EV-to-EBIT | -1.31 | |||||
| EV-to-Forward-EBIT | -5.24 | |||||
| EV-to-EBITDA | -1.57 | |||||
| EV-to-Revenue | 0.76 | |||||
| EV-to-Forward-Revenue | 1.01 | |||||
| EV-to-FCF | -0.71 | |||||
| Price-to-GF-Value | 0.48 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -76.34 | |||||
| FCF Yield % | -252.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agenus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 160.427 | ||
| EPS (TTM) ($) | -68.77 | ||
| Beta | 1.51 | ||
| 3-Year Sharpe Ratio | -0.9 | ||
| 3-Year Sortino Ratio | -1.05 | ||
| Volatility % | 94.21 | ||
| 14-Day RSI | 35.39 | ||
| 14-Day ATR ($) | 0.280852 | ||
| 20-Day SMA ($) | 3.421 | ||
| 12-1 Month Momentum % | -71.64 | ||
| 52-Week Range ($) | 2.5 - 19.688 | ||
| Shares Outstanding (Mil) | 23.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agenus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agenus Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agenus Inc Frequently Asked Questions
What is Agenus Inc(AGEN)'s stock price today?
The current price of AGEN is $2.86. The 52 week high of AGEN is $19.69 and 52 week low is $2.50.
When is next earnings date of Agenus Inc(AGEN)?
The next earnings date of Agenus Inc(AGEN) is 2025-03-11.
Does Agenus Inc(AGEN) pay dividends? If so, how much?
Agenus Inc(AGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers